Anxious depression.

R B Lydiard; O Brawman-Mintzer

Home/Archive/PubMed

PubMed · 9840193

Anxious depression.

R B Lydiard·O Brawman-Mintzer

View original source ↗Export metadata ↓

Abstract

Depression and anxiety often coexist. When they co-occur, both anxiety and depression appear to be more severe. Increased morbidity, poorer acute and long-term outcome, increased suicide risk, and increased treatment resistance are associated with comorbid anxiety and depression. The term anxious depression has taken on newer meaning with the changes in the diagnostic system that allow for concurrent diagnosis of anxiety disorders and major depression. Attention to the subtype of both anxiety and depression could have significant effects on treatment choice by the clinician. The authors review some historical aspects of anxious depression and also highlight some of the advances in differential diagnosis and treatment of coexisting depression and anxiety.

Explore related subjects

Anti-Anxiety Agents Antidepressive Agents Anxiety Disorders Comorbidity Depressive Disorder Diagnosis, Differential Humans Monoamine Oxidase Inhibitors Obsessive-Compulsive Disorder Panic Disorder Phobic Disorders Stress Disorders, Post-Traumatic Terminology as Topic Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R B Lydiard, O Brawman-Mintzer. 1998. Anxious depression.. https://pubmed.ncbi.nlm.nih.gov/9840193/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

[Long-term use of benzodiazepines].

Benzodiazepines are the most prescribed drugs in the Netherlands. There is scarcely an indication for long-term benzodiazepine use. Long-term use may lead to dependency and is associated with an increased risk of accidents/falls and cognitive function impairment. Therefore national and international guidelines advocate a conservative prescription policy, especially with respect to long-term prescription. It appears that these guidelines are not followed in practice. A standard sized general practice in the Netherlands contains, on average, 75 long-term benzodiazepine users. There appear to be both patient and GP related factors which influence the maintenance of this long-term use of benzodiazepines.

Anti-Anxiety Agents↗

PubMed2001

[Treatment methods for discontinuation of long-term benzodiazepine use].

Treatment strategies for discontinuing long-term benzodiazepine usage can be divided into minimal interventions and gradual discontinuation programs. Minimal interventions invite patients to quit their long-term benzodiazepine usage on their own by making them aware of the adverse effects. This type of intervention is successful in about one fifth of patients. Gradual discontinuation programs are more extensive interventions in order to help those patients who are unable to discontinue benzodiazepine use on their own. These programs are successful in two-thirds of the patients and can be combined with additional pharmacological or psychological treatment. Once the withdrawal symptoms have diminished, most patients have an improved psychological functioning compared to when they were using benzodiazepines. Furthermore, no increase in medical consumption has been found.

Anti-Anxiety Agents↗

PubMed2001

Ketazolam.

The title compound, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, C20H17ClN2O3, is a benzodiazepine with an additional d-face-fused heterocyclic ring. In the molecule, a dihedral angle of 86.2 (1) degrees is formed by the planes of the phenyl and benzo rings and the former is axially oriented from the core, i.e. the fused 6,7,6-tricyclic system. Both heterocycles in the core suffer significant deviations from planarity. The central diazepine ring is a twist-boat and the oxazine ring exhibits a conformation intermediate between half-chair and sofa.

Anti-Anxiety Agents↗